ClinicalTrials.gg
CompletedNCT00762736Updated Feb 28, 2012

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Pioglitazone and azilsartan and Pioglitazone and azilsartan in Diabetes Mellitus, sponsored by Takeda. Completed at 78 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-28.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
704
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
11th of 122
704 · median 103
Started
2004
with 5 others
Phase 2
8 of 122
1 open now
Registered
47th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 11th largest by enrollment, is one of 6 that started in 2004, is one of 8 in phase 2, and was the 47th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of pioglitazone, once daily (QD), combined with azilsartan in the treatment of subjects with Type 2 Diabetes Mellitus.

Read the detailed description

Diabetes is a chronic disease with multiple metabolic defects that result in hyperglycemia arising from inadequate insulin activity. Type 2 diabetes has a genetic predisposition, but lifestyle, body constitution and age play important roles in determining its time of onset and severity. Type 2 diabetes is usually the result of a progression from reduced sensitivity of hepatic and peripheral-tissue cells to circulating insulin (i.e., insulin resistance) to a progressive inability of the body to produce adequate insulin to overcome insulin resistance (i.e., insulin deficiency due to beta cell insufficiency) resulting in impaired glucose tolerance and ultimately overt diabetes. In the United States, an estimated 15.7 million people have diabetes, with type 2 diabetes occurring in approximately 90-95% of cases.

Therapeutic agents have been developed to address each of the major functional metabolic defects associated with type 2 diabetes: decreased beta-cell function, elevated hepatic glucose output, and insulin resistance. The oral therapeutic agents used in the treatment of type 2 diabetes can be separated into the following four categories based on their mechanisms of action: insulin secretagogues, inhibitors of hepatic glucose output, inhibitors of complex carbohydrate breakdown in the intestine and insulin sensitizers.

Thiazolidinediones reduce insulin resistance by enhancing insulin sensitivity in muscle cells, adipose tissue, and hepatic cells (inhibiting hepatic gluconeogenesis) with no direct impact on insulin secretion. Thus thiazolidinediones improve glycemic control and result in reduced levels of circulating insulin. Peroxisome proliferator-activated receptors are found in tissues important for insulin action, such as adipose tissue, skeletal muscle, and the liver. The greatest concentration of peroxisome proliferator-activated receptors -gamma receptors is in adipose tissue. Pioglitazone HCl (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd.

Research suggests that Angiotensin II receptor blockers are involved in endothelial and cardiovascular function, and in insulin sensitization and obesity. TAK-536 (azilsartan) is an angiotensin II receptor antagonist with affinity for and selective antagonistic activity at the angiotensin II type 1 receptor.

This study was designed to evaluate the efficacy, safety, and tolerability of pioglitazone in combination with azilsartan in subjects with type 2 diabetes.

Study participation is anticipated to be approximately 6 months.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 704 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had type 2 diabetes, with a value of greater than or equal to 8.0% or less than 10.0% at Screening.
  • Females of who were sexually active agreed to use adequate , and were neither pregnant nor lactating from Screening throughout the duration of the study.
  • Received antihypertensive therapy and must have been on a stable dose for a minimum of 8 weeks prior to Screening.
  • Had clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory unless the results were deemed not for inclusion into this study by the investigator or sponsor.
  • Had been on stable diet and exercise program and oral anti-glycemic therapy including sulfonylurea or metformin for 8 weeks prior to Screening.

Exclusion criteria

Exclusion Criteria:

  • Had a value less than 8.0% or greater than 10.0% at Screening.
  • Was taking an angiotensin II receptor blocker.
  • Had uncontrolled hypertension defined as systolic blood pressure greater than 160 mm Hg and diastolic blood pressure greater than 100 mm Hg. - Had a systolic blood pressure less than or equal to 110 mm Hg and/or diastolic blood pressure less than or equal to 60 mm Hg.
  • Was taking or was expected to take the following medications:

    • antidiabetic agents (other than sulfonylurea or metformin)
    • tricyclic antidepressants
    • monoamine oxidase inhibitors
    • phenothiazines
    • diet medications
    • amphetamines or their derivatives
    • lithium
    • common cold medications with chronic use
    • nonsteroidal anti-inflammatory drugs with chronic use (including aspirin greater than 325 mg/day or cyclooxygenase 2 inhibitors).
  • Had unstable angina or heart failure of any etiology with functional class III or IV.
  • Had a history of myocardial infarction.
  • Had cardiac conduction defects (eg, second or third degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation or flutter).
  • Had secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).
  • Had a history of collagen vascular disorder (eg, systemic lupus erythematosus, scleroderma) within the last 5 years.
  • Had a greater than 39 kg/m2.
  • Had significant, moderate-to-severe renal dysfunction (creatinine greater than 2.4 mg/dL). If receiving metformin, a creatinine greater than 1.5 mg/dL for male subjects or greater than 1.4 mg/dL for female subjects led to exclusion.
  • Had a history of drug abuse or a history of alcohol abuse within the past 2 years.
  • Had a previous history of cancer, other than basal cell carcinoma, that had not been in remission for at least 5 years prior to the first dose of study drug.
  • Had type 2 diabetes with clinically important retinopathy or peripheral or autonomic neuropathy.
  • Had an or aspartate aminotransferase level of greater than 2.5 times the , active liver disease, or jaundice.
  • Was participating in another study or had participated in an investigational study within 30 days prior to randomization.
  • Had any other serious disease or condition at Screening (or randomization) that might have compromised subject safety, affected , or made it difficult to successfully manage and follow the subject according to the protocol.
  • Was hypersensitive to angiotensin II receptor blockers.
  • Was hypersensitive to thiazolidinediones.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
704 participants (actual)

Study arms

  • Experimental
    Pioglitazone 15 mg QD + Azilsartan 5 mg QD

    Drug: Pioglitazone and azilsartan

  • Experimental
    Pioglitazone 15 mg QD + Azilsartan 40 mg QD

    Drug: Pioglitazone and azilsartan

  • Active comparator
    Pioglitazone 15 mg QD

    Drug: Pioglitazone

  • Experimental
    Pioglitazone 45 mg QD + Azilsartan 5 mg QD

    Drug: Pioglitazone and azilsartan

  • Experimental
    Pioglitazone 45 mg QD + Azilsartan 40 mg QD

    Drug: Pioglitazone and azilsartan

  • Active comparator
    Pioglitazone 45 mg QD

    Drug: Pioglitazone

Interventions

  • DrugPioglitazone and azilsartan

    Drug pages: Pioglitazone · Azilsartan

    Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.

    Also known as: ACTOS®, AD4833, TAK-536

  • DrugPioglitazone and azilsartan

    Drug pages: Pioglitazone · Azilsartan

    Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.

    Also known as: ACTOS®, AD4833, TAK-536

  • Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.

    Also known as: ACTOS®, AD4833

  • DrugPioglitazone and azilsartan

    Drug pages: Pioglitazone · Azilsartan

    Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.

    Also known as: ACTOS®, AD4833, TAK-536

  • DrugPioglitazone and azilsartan

    Drug pages: Pioglitazone · Azilsartan

    Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.

    Also known as: ACTOS®, AD4833, TAK-536

  • Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.

    Also known as: ACTOS®, AD4833

07

What researchers measure

Primary outcomes

  1. Change from Baseline in glycosylated hemoglobin.

    Time frame: Week 24 or Final Visit

Secondary outcomes

  1. Change from Baseline in glycosylated hemoglobin.

    Time frame: Weeks 12, 16, 20, and 24 or Final Visit

  2. Change from Baseline in fasting plasma glucose.

    Time frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit

  3. Change from Baseline in total cholesterol.

    Time frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit

  4. Change from Baseline in high-density lipoprotein.

    Time frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit

  5. Change from Baseline in low-density lipoprotein.

    Time frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit

  6. Change from Baseline in triglycerides.

    Time frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit

  7. Change from Baseline in body weight.

    Time frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit

  8. Change from Baseline in systolic and diastolic blood pressure.

    Time frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit

  9. Change from Baseline in incidence of edema (peripheral).

    Time frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit

  10. Change from Baseline in microalbuminuria excretion.

    Time frame: Week 24 or Final Visit

  11. Change from Baseline in high-sensitivity C-reactive protein.

    Time frame: Weeks 12 and 24 or Final Visit

  12. Change from Baseline in matrix metalloproteinase-9.

    Time frame: Weeks 12 and 24 or Final Visit

08

Study locations

78 sites
  • Birmingham,, Alabama, United States
  • Huntsville, Alabama, United States
  • Sierra Vista, Arizona, United States
  • Sun City, Arizona, United States
  • Tucson, Arizona, United States
  • Burbank, California, United States
  • Escondido, California, United States
  • Irvine, California, United States
  • La Jolla, California, United States
  • National City, California, United States
  • Riverside, California, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Spring Valley, California, United States
  • Coral Gables, Florida, United States
  • Deland, Florida, United States
  • Hollywood, Florida, United States
  • Miami, Florida, United States
  • New Port Richey, Florida, United States
  • Opalocka, Florida, United States
  • Pembroke Pines, Florida, United States
  • Sarasota, Florida, United States
  • Vero Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Warner Robins, Georgia, United States
  • Honolulu, Hawaii, United States
  • Lihue, Hawaii, United States
  • Chicago, Illinois, United States
  • Dyersburg, Indiana, United States
  • Overland Park, Kansas, United States
  • Wichita, Kansas, United States
  • New Orleans, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Salisbury, Massachusetts, United States
  • Cadillac, Michigan, United States
  • Detroit, Michigan, United States
  • Livonia, Michigan, United States
  • Kansas City, Missouri, United States
  • St. Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • North Las Vegas, Nevada, United States
  • Berlin, New Jersey, United States
  • Blackwood, New Jersey, United States
  • Trenton, New Jersey, United States
  • Albany, New York, United States
  • Kingston, New York, United States
  • Charlotte, North Carolina, United States
  • Marion, Ohio, United States
  • Clinton, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Allentown, Pennsylvania, United States
  • Altoona, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Scotland,, Pennsylvania, United States
  • Woonsocket, Rhode Island, United States
  • Greer, South Carolina, United States
  • Arlington, Texas, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Midland,, Texas, United States
  • North Richard Hills, Texas, United States
  • San Antonio, Texas, United States
  • Renton, Washington, United States
  • Buenos Aires, Argentina
  • Cordoba, Argentina
  • Rosario-Santa Fe, Argentina
  • Santa Fe, Argentina
  • Ushuaia - Tierre del Fuego, Argentina
  • Santiago, Chile
  • Aguascalientes, Mexico
  • Cuernavaca, Mexico
  • Durango, Mexico
  • Guadalajara, Mexico
  • Mexico City, Mexico
  • Pueblo, Mexico
  • Ica, Peru
  • Lima, Peru
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2008
First posted
Sep 30, 2008
Start
Jul 2004
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Last update
Feb 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00762736
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 30, 2008
Start date
Jul 2004
Primary completion
Oct 2005
Completion
Oct 2005
Last update
Feb 28, 2012

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Azilsartan

Start the discussion